All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...

The move comes as the company faces ‘several challenges’ around the launching of medicines and timed out patents ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

THE family of a "beloved father and husband" who took his own life after Covid-19 vaccine complications are fighting for justice.

In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

DelveInsight's Inflammatory Bowel disease market Report provides comprehensive insights into the epidemiology and market dynamics across the 7MM. LAS VEGAS , NV, UNITED STATES, January 30, 2025 ...

Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots ...

UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Dear reader, China’s biotechnology sector has rapidly emerged as one of the fastest-growing industries, with Chinese players ...

The latest trading day saw Astrazeneca (AZN) settling at $70.25, representing a +0.95% change from its previous close.